Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Texas
Clinical trial register · United States · industry-sponsored

Clinical Trials in Texas, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9124 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 09 Oct 2026, 03:16 UTC
9124
Studies in scope
industry-sponsored, all four open statuses
4956
Recruiting now
open to new participants
2195
Lead sponsors
across recruiting studies
Top states
California 231 Florida 173 Arizona 113 Illinois 109 Georgia 105
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca53 Novartis Pharmaceuticals44 Eli Lilly and Company33 Merck Sharp & Dohme LLC31 GlaxoSmithKline31 Clear sponsor filter
State
California231 Florida173 Arizona113 Illinois109 Georgia105
All 48 states
Target enrolment
to

Trials with a site in Texas

53 of 9124 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
AstraZeneca
Phase 3
750
Florida, Georgia, Illinois, Michigan, Minnesota, Ohio, Texas, Washington
2026-08-25
Not yet open
AstraZeneca
Phase 1
30
Arizona, Florida, Texas
2026-08-24
Recruiting
AstraZeneca
Phase 3
150
California, Georgia, Illinois, Kentucky, Nevada, South Dakota, Tennessee, Texas
2026-06-15
Recruiting
AstraZeneca
Phase 1/2
152
California, Florida, Louisiana, Minnesota, Nebraska, New York, Oregon, Texas
2026-06-03
Recruiting
AstraZeneca
Phase 2
43
California, Iowa, Maryland, New York, Texas
2026-03-28
Recruiting
AstraZeneca
Phase 1
28
Arizona, California, Florida, Texas
2026-03-20
Recruiting
AstraZeneca
Phase 1/2
180
New York, Rhode Island, Texas, Virginia
2026-03-17
Recruiting
AstraZeneca
Phase 1/2
84
Illinois, New York, North Carolina, Oregon, Texas
2026-01-09
Recruiting
AstraZeneca
Phase 1
20
California, Texas
2026-01-06
Recruiting
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
NCT07201558Rheumatoid Arthritis, Systemic Lupus Erythematosus
DrugSurovatamig
AstraZeneca
Phase 1
48
Alabama, California, Florida, Missouri, Texas
2025-12-02
Recruiting
AstraZeneca
Phase 1
40
North Carolina, Texas, Virginia
2025-11-25
Recruiting
AstraZeneca
Phase 1/2
83
California, Florida, Illinois, Iowa, Tennessee, Texas
2025-11-12
Recruiting
AstraZeneca
Phase 1
40
Alabama, California, Florida, Kansas, Maryland, Minnesota, Texas
2025-11-10
Recruiting
AstraZeneca
Phase 1
72
Florida, Texas
2025-11-03
Recruiting
AstraZeneca
Phase 3
100
Florida, Indiana, Nebraska, New York, Texas, Washington
2025-10-30
Recruiting
AstraZeneca
Phase 2
278
California, Georgia, Maryland, Texas, Virginia
2025-08-07
Recruiting
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
NCT07115043Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
DrugRilvegostomig
AstraZeneca
Phase 1/2
120
Michigan, Missouri, Pennsylvania, Texas, Virginia
2025-07-29
Recruiting
AstraZeneca
Phase 1
124
California, Illinois, Michigan, Minnesota, Texas
2025-06-09
Recruiting
AstraZeneca
Phase 1
136
California, Florida, Maryland, Texas
2025-05-27
Active, closed
Study for AZD4360 in Participants With Advanced Solid Tumours
NCT06921928Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
AstraZeneca
Phase 1/2
31
California, Rhode Island, Texas
2025-04-29
Recruiting
AstraZeneca
Phase 1/2
304
California, Maryland, Massachusetts, Missouri, New Jersey, Texas
2025-03-27
Active, closed
An Ophthalmic Safety Study in Patients With Breast Cancer
NCT06767462Ophthalmic Safety in Patients With Breast Cancer
AstraZeneca
Observational
160
California, Iowa, North Carolina, Pennsylvania, South Dakota, Tennessee, Texas
2025-03-05
Active, closed
AstraZeneca
Phase 3
310
California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Oklahoma, Texas
2024-09-30
Recruiting
AstraZeneca
Phase 1/2
174
California, Massachusetts, Minnesota, New Jersey, New York, North Carolina, Texas, Washington
2024-09-18
Active, closed
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
NCT06147037Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer
AstraZeneca
Phase 1
13
California, Illinois, Nebraska, Ohio, Texas, Washington
2024-07-31
Active, closed
AstraZeneca
Phase 4
1,511
California, Kentucky, Massachusetts, Michigan, Minnesota, North Carolina, Pennsylvania, Texas
2024-05-10
Active, closed
AstraZeneca
Phase 2
142
New York, Texas, Virginia
2024-02-22
Recruiting
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
NCT06137144Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)
DrugsAZD3470·Keytruda·Pembrolizumab
AstraZeneca
Phase 1/2
161
California, Florida, Georgia, Massachusetts, New York, Pennsylvania, Texas
2024-01-23
Active, closed
AstraZeneca
Phase 1
98
California, Florida, Maryland, Texas
2024-01-16
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Alabama, California, Florida, Georgia, Illinois, New York, Texas, Virginia
2023-12-29
Recruiting
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
DrugsL-leucovorin·Nanoliposomal Irinotecan·Onivyde·Sonesitatug Vedotin
AstraZeneca
Phase 2
226
California, Kentucky, New York, Rhode Island, Texas
2023-12-13
Active, closed
AstraZeneca
Phase 2
108
New Jersey, New York, Ohio, Pennsylvania, Texas
2023-12-13
Recruiting
AstraZeneca
Phase 1/2
564
Missouri, Rhode Island, Tennessee, Texas
2023-12-05
Recruiting
AstraZeneca
Phase 1/2
695
California, Illinois, Massachusetts, New York, Oregon, Texas, Virginia
2022-06-24
Active, closed
AstraZeneca
Phase 1/2
174
Michigan, New York, South Carolina, Texas
2022-06-02
Active, closed
AstraZeneca
Phase 1/2
36
Ohio, Pennsylvania, Texas, Virginia
2022-01-21
Active, closed
AstraZeneca
Phase 2
126
California, Georgia, Idaho, Massachusetts, Michigan, New York, Oregon, Texas
2021-12-10
Recruiting
AstraZeneca
Phase 1
304
California, Kansas, Maryland, Michigan, New York, Texas, Virginia, Washington
2021-03-09
Active, closed
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
NCT04594642B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
DrugSurovatamig
AstraZeneca
Phase 1
226
Florida, Kentucky, New Jersey, North Carolina, Ohio, Pennsylvania, Texas, Wisconsin
2021-03-02
Active, closed
AstraZeneca
Phase 1
155
California, Missouri, New Jersey, Ohio, Pennsylvania, Texas, Virginia
2021-02-02
Active, closed
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
NCT04639219Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
102
California, Indiana, Massachusetts, New Jersey, New York, Texas, Virginia
2020-12-30
Active, closed
AstraZeneca
Phase 1/2
245
Florida, New York, Ohio, Tennessee, Texas, Virginia
2020-12-28
Active, closed
AstraZeneca
Phase 1
138
New York, North Carolina, Tennessee, Texas
2020-12-17
Active, closed
AstraZeneca
Phase 3
358
California, Massachusetts, New Hampshire, New York, Texas, Virginia, Washington
2020-12-16
Active, closed
AstraZeneca
Phase 3
957
California, Florida, Indiana, Kentucky, Massachusetts, New York, Tennessee, Texas
2020-11-17
Active, closed
AstraZeneca
Phase 1/2
702
Massachusetts, New York, Oklahoma, Texas
2020-11-12
Active, closed
AstraZeneca
Phase 3
640
Georgia, Kentucky, Texas, Virginia, West Virginia
2020-10-19
Active, closed
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
477
California, Illinois, Indiana, Massachusetts, New Jersey, New York, North Carolina, Texas
2020-08-18
Active, closed
AstraZeneca
Phase 2
452
Maryland, Massachusetts, New York, Texas
2020-06-03
Active, closed
AstraZeneca
Phase 3
140
Colorado, Michigan, Minnesota, New Mexico, New York, Pennsylvania, Texas, Washington
2019-10-29
Active, closed
AstraZeneca
Phase 2
401
Florida, Missouri, Pennsylvania, Tennessee, Texas
2018-12-21
Active, closed
AstraZeneca
Phase 1/2
243
Arizona, Maryland, Massachusetts, Michigan, Missouri, Texas, Virginia
2018-12-21
Active, closed
AstraZeneca
Phase 3
953
California, Kentucky, New Jersey, New Mexico, New York, Ohio, Pennsylvania, Texas
2015-11-03
Rows per page Showing 1–53 of 53
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 October 2026. https://priyalifescience.com/clinical-trials-usa/state/texas

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,124 studies in total at the last sync on 09 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 53 of those studies with a site in Texas that also match the filters currently applied.

How many clinical trials are recruiting in Texas?

25 of the 53 studies on this page are recruiting new participants as of the 09 Oct 2026, 03:16 UTC sync. A further 2 have not yet opened recruitment, 26 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Texas), 53 studies
PhaseStudiesRecruitingShare
Phase 1/2171132.1%
Phase 115928.3%
Phase 210318.9%
Phase 39217%
Observational101.9%
Phase 4101.9%

Most active sponsors

Lead sponsors with the most studies (Texas)
Lead sponsorStudiesRecruiting
AstraZeneca5325
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.